AVIDITY BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.78 USD | +6.84% |
|
+2.75% | +184.86% |
| 04/04 | Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing | MT |
| 04/04 | Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing | MT |
Chart calendar Avidity Biosciences, Inc.
7a4.4rubbSDBz8LDBay7kPzSA1vehYEUbhr6uBwTl7eni48.mt7WP0OUgbqNQdqI19G5Og22zMdyHEKOiXRw--Tm7uW7g8IOdq77hqRvyw~b5a8256c41bfa3203bed8539af9025ac
Upcoming events on Avidity Biosciences, Inc.
Past events on Avidity Biosciences, Inc.
| 10/04/2024 11:45 pm | Needham Healthcare Conference |
| 03/04/2024 10:10 pm | Cantor Fitzgerald Muscular Dystrophy Symposium |
| 13/03/2024 10:35 pm | Barclays Global Healthcare Conference |
| 13/03/2024 12:30 am | Leerink Partners Global Biopharma Conference |
| 06/03/2024 04:30 am | Muscular Dystrophy Association Clinical & Scientific Conference - AOC 1001 |
| 06/03/2024 12:00 am | TD Cowen Health Care Conference |
| 05/03/2024 04:30 am | Muscular Dystrophy Association Clinical & Scientific Conference - AOC 1044 |
| 04/03/2024 06:30 pm | Muscular Dystrophy Association Clinical & Scientific Conference |
| 29/02/2024 02:35 am | Q4 2023 Earnings Release |
| 28/11/2023 11:00 pm | Evercore ISI HealthCONx Conference |
| 09/11/2023 02:35 am | Q3 2023 Earnings Release |
| 10/10/2023 08:30 pm | BMO BioPharma Spotlight Series: Inflammation & Immunology |
| 07/10/2023 05:15 pm | World Muscle Society Congress - Topline Safety and Efficacy Data Analysis of Phase 1/2 Clinical Tria |
| 06/10/2023 11:30 pm | World Muscle Society Congress - More Prevalent Comorbidities, Healthcare Costs, and Service Utilizat |
| 05/10/2023 12:00 am | World Muscle Society Congress - Sex-related Utilization Differences in the 12-months After a Diagnos |
| 03/10/2023 06:30 pm | Chardan Genetic Medicines Conference |
| 26/09/2023 07:25 pm | Cantor Global Healthcare Conference |
| 09/09/2023 10:00 pm | Myotonic Dystrophy Foundation Conference - Topline Data Analysis of the Phase 1/2 Clinical Trial |
| 09/09/2023 10:00 pm | Myotonic Dystrophy Foundation Conference - AOC 1001 Demonstrates DMPK Reduction |
| 07/09/2023 10:00 pm | MDF Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 2,32 | 6,79 5,45 24.53% | 9,33 9,53 -2.09% | 9,22 8,33 10.75% | 9,56 19,6 -51.18% | 13,5 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -43,9 -43,5 -1% | -117 -115 -2.1% | -178 -182 2.48% | -233 -229 -1.79% | -267 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -44,3 -42,1 -5.25% | -118 -112 -5.69% | -179 -176 -1.64% | -236 -215 -9.38% | -281 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -44,4 -41,5 -7.01% | -118 -112 -5.62% | -174 -174 -0.24% | -212 -195 -8.63% | -269 |
|
Net income Million USD | Released Forecast Spread | 0,00 | -44,4 -41,5 -7.01% | -118 -112 -5.23% | -174 -173 -0.32% | -212 -200 -6.21% | -274 |
|
EPS USD | Released Forecast Spread | -4,32 | -2,05 -1,80 -13.89% | -2,85 -2,73 -4.59% | -3,34 -3,35 0.43% | -2,91 -2,76 -5.43% | -3,14 |
| Announcement Date | 03/04/20 | 15/03/21 | 01/03/22 | 28/02/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 1,85 2,23 -17.07% | 1,80 1,90 -5.53% | 2,18 2,06 5.6% | 2,48 2,15 15.67% | 2,77 1,88 47.68% | 2,23 1,75 27.41% | 2,32 1,89 22.82% | 2,82 1,84 52.76% | 2,19 12,2 -82.04% | 2,57 | 2,46 | 4,60 | 2,46 | |
|
EBIT Million USD | Released Forecast Spread | -38,5 -30,8 -25.15% | -34,5 -35,4 2.78% | -46,3 -36,3 -27.52% | -44,9 -48,4 7.16% | -53,2 -50,3 -5.75% | -57,6 -54,8 -5.13% | -52,6 -59,0 10.84% | -58,6 -59,6 1.57% | -66,7 -46,5 -43.54% | -68,1 | -69,6 | -69,8 | -75,9 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -38,5 -30,9 -24.92% | -34,2 -36,7 6.72% | -45,7 -34,5 -32.46% | -43,6 -47,6 8.42% | -50,5 -48,2 -4.7% | -52,4 -55,5 5.66% | -47,0 -58,2 19.15% | -52,4 -55,2 5.15% | -60,4 -43,6 -38.72% | -64,5 | -65,8 | -66,6 | -71,7 | |
|
Net income Million USD | Released Forecast Spread | -38,5 -31,2 -23.39% | -34,2 -38,5 11.15% | -45,7 -35,2 -29.82% | -43,6 -48,3 9.79% | -50,5 -48,4 -4.22% | -52,4 -56,2 6.82% | -47,0 -58,4 19.45% | -52,4 -55,7 6.04% | -60,4 -48,0 -25.82% | -65,6 | -67,0 | -68,2 | -72,9 | |
|
EPS USD | Released Forecast Spread | -0,84 -0,70 -20.43% | -0,71 -0,80 11.03% | -0,92 -0,75 -22.2% | -0,82 -0,93 12.1% | -0,88 -0,89 0.8% | -0,74 -0,85 12.94% | -0,66 -0,80 17.35% | -0,71 -0,76 6.17% | -0,79 -0,66 -19.7% | -0,77 | -0,76 | -0,77 | -0,82 | -0,85 |
| Announcement Date | 01/03/22 | 10/05/22 | 09/08/22 | 08/11/22 | 28/02/23 | 09/05/23 | 08/08/23 | 08/11/23 | 28/02/24 | - | - | - | - | - |
| 06/05/2024 04:30 pm | AXSOME THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 07/05/2024 | BIOTEST AG: Q1 2024 Earnings Release |
| 07/05/2024 | AVIDITY BIOSCIENCES, INC.: Q1 2024 Earnings Release (Projected) |
| 07/05/2024 | REVANCE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 07/05/2024 | APELLIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 07/05/2024 11:30 am | BIOGAIA AB: Q1 2024 Earnings Release |
| 08/05/2024 | ADMA BIOLOGICS, INC.: Q1 2024 Earnings Release (Projected) |
| 08/05/2024 | INTRA-CELLULAR THERAPIES, INC.: Q1 2024 Earnings Release (Projected) |
| 08/05/2024 | CATALYST PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 08/05/2024 | ZAI LAB LIMITED: Q1 2024 Earnings Release |
Past sector events for Avidity Biosciences, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- RNA Stock
- Calendar Avidity Biosciences, Inc.
